Cathay Biotech Inc.
688065.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | CN¥874,273 | CN¥894,998 | CN¥775,770 | CN¥742,828 |
| % Growth | -2.3% | 15.4% | 4.4% | – |
| Cost of Goods Sold | CN¥555,258 | CN¥648,124 | CN¥514,851 | CN¥619,614 |
| Gross Profit | CN¥319,015 | CN¥246,874 | CN¥260,919 | CN¥123,214 |
| % Margin | 36.5% | 27.6% | 33.6% | 16.6% |
| R&D Expenses | CN¥55,368 | CN¥62,648 | CN¥60,551 | CN¥64,547 |
| G&A Expenses | CN¥0 | CN¥47,872 | CN¥43,023 | CN¥35,720 |
| SG&A Expenses | CN¥68,198 | CN¥63,520 | CN¥56,665 | CN¥49,757 |
| Sales & Mktg Exp. | CN¥0 | CN¥15,648 | CN¥13,642 | CN¥14,037 |
| Other Operating Expenses | CN¥64,619 | -CN¥63,372 | -CN¥17,981 | -CN¥153,553 |
| Operating Expenses | CN¥188,185 | CN¥62,796 | CN¥99,234 | -CN¥39,249 |
| Operating Income | CN¥130,830 | CN¥184,079 | CN¥161,686 | CN¥162,463 |
| % Margin | 15% | 20.6% | 20.8% | 21.9% |
| Other Income/Exp. Net | CN¥30,477 | -CN¥7 | -CN¥3,645 | -CN¥1,820 |
| Pre-Tax Income | CN¥161,307 | CN¥184,072 | CN¥158,041 | CN¥160,643 |
| Tax Expense | CN¥22,594 | CN¥24,198 | CN¥33,722 | CN¥24,488 |
| Net Income | CN¥142,007 | CN¥171,717 | CN¥136,950 | CN¥143,784 |
| % Margin | 16.2% | 19.2% | 17.7% | 19.4% |
| EPS | 0.2 | 0.24 | 0.23 | 0.25 |
| % Growth | -16.7% | 4.3% | -8% | – |
| EPS Diluted | 0.2 | 0.24 | 0.23 | 0.25 |
| Weighted Avg Shares Out | 718,949 | 718,949 | 595,435 | 582,098 |
| Weighted Avg Shares Out Dil | 718,949 | 718,949 | 595,435 | 582,098 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥48,103 | CN¥66,820 | CN¥31,188 | CN¥43,206 |
| Interest Expense | CN¥949 | CN¥746 | CN¥7,000 | CN¥5,252 |
| Depreciation & Amortization | CN¥0 | CN¥77,703 | CN¥78,980 | CN¥78,980 |
| EBITDA | CN¥164,269 | CN¥186,675 | CN¥222,126 | CN¥72,540 |
| % Margin | 18.8% | 20.9% | 28.6% | 9.8% |